Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
GCC Pharmaceutical Market Clinical Trials Outlook 2030
The GCC pharmaceutical market, led by Saudi Arabia, is rapidly expanding due to factors like population growth and lifestyle diseases. The market is expected to exceed US$ 12 Billion by 2030, with branded and imported drugs dominating. Clinical trials in the region involve over 250 drugs, and healthcare transformation programs are driving growth. Local manufacturing is increasing, especially in generics and biosimilars, while digital health innovations are enhancing market efficiency.
Comprehensive Market Analysis on Precision Medicine Market
Precision Medicine Market valued at USD 78.6 Billion in 2023, projected to reach USD 156.1 Billion by 2030, driven by technological advancements, rising chronic diseases, and collaborations. North America leads, followed by Europe and Asia-Pacific. Key players include AstraZeneca, Illumina, Johnson & Johnson, and Novartis.
Core8 Group to Establish Vietnam's First Comprehensive Biotechnology Incubator
Core8 Group announces establishment of Vietnam’s first comprehensive biotechnology incubator, Core8 BioValley, in Long An Province, featuring advanced facilities for biomedical and agricultural sectors, fostering global partnerships, and enhancing Vietnam’s role in international markets.
FDA Grants Breakthrough Therapy Designation to Sac-TMT for Previously Treated NSCLC
The FDA granted breakthrough therapy designation to sacituzumab tirumotecan (sac-TMT) for treating advanced or metastatic nonsquamous NSCLC with EGFR mutations (exon 19 deletion or exon 21 L858R) that progressed after TKI and platinum-based chemotherapy. This decision is based on phase 2 expansion cohort data from a phase 1/2 study. Sac-TMT is an investigational TROP2-directed ADC, currently undergoing phase 3 trials in various solid tumors, including NSCLC (TroFuse-004 and TroFuse-009).
Related Clinical Trials:
Fred Saad on the Phase III Prostate Cancer ARANOTE Trial of Darolutamide and ADT
The ARANOTE trial demonstrated that darolutamide plus androgen-deprivation therapy (ADT) without chemotherapy improved radiological progression-free survival by 46% in metastatic hormone-sensitive prostate cancer (mHSPC) patients compared to placebo plus ADT (HR 0.54, 95% CI 0.41-0.71, P<0.0001). The combination showed consistent benefits across subgroups, including high- and low-volume disease, and improved overall survival (OS) rates at 24 months (79.8% vs. 75.5%). Darolutamide also exhibited better tolerability with lower rates of fatigue and adverse event-related discontinuation compared to placebo.
GSK taps a startup for shot at Alzheimer's drug
Muna Therapeutics, a biotech company, collaborates with GSK to analyze brain tissue samples to identify new targets for Alzheimer’s drugs, potentially worth hundreds of millions. GSK provides €33.5 million upfront and up to €140 million in milestone payments per target. Muna will expand its dataset and find molecular switches, while GSK leads drug development and commercialization. Muna, formed in 2020, merges with K5 Therapeutics and raises $73 million. GSK, returning to neuroscience, sees Muna’s technology as key to understanding neurodegenerative diseases.
Advancing the Precision Oncology Agenda in Europe
EFPIA highlights EU's roadmap for precision oncology to address rising cancer burden, despite forecasted mortality rate declines. Stakeholder roundtable in Brussels aims to improve personalized cancer treatment. EU initiatives, including AI-powered cancer care and the DigiONE pilot, aim to advance precision medicine. A gold-standard cancer data management system is necessary for innovative precision medicine access, emphasizing standardized data formats, robust privacy, and professional education.
Biotechnology Market: Projected Significant CAGR
The Biotechnology Market is projected to grow at a CAGR of 15.4% from 2024 to 2031, driven by advancements in genetic research, personalized medicine, and agricultural biotechnology. Key players include F. Hoffmann-La Roche Ltd, Pfizer, and Merck KGaA. The market focuses on drug development, genetic engineering, diagnostics, and biofuels, with segments like DNA Sequencing and Bioinformatics. Regional analysis covers North America, Europe, Asia-Pacific, South America, and Middle East & Africa.
The US FDA Approves iBox, French Algorithm for Predicting Kidney Graft Survival
iBox, developed by Prof. Alexandre Loupy, predicts kidney graft fate up to 10 years post-transplant. Validated in 12 centers and 3 trials, it received FDA approval in 2022, supported by AST, TTC, and major pharma. iBox optimizes treatment, reduces costs, and may revolutionize predictive medicine beyond kidney transplants.
Dermatology Month in Review | November 2024
November's dermatology highlights include FDA approval of bimekizumab for HS, resubmissions for dupilumab and pz-cel, obesity's link to psoriasis, JNJ-2113's efficacy in psoriasis, stress's impact on skin aging, and factors affecting HS diagnostic wandering.
© Copyright 2024. All Rights Reserved by MedPath